Tenaya Therapeutics, Inc. (TNYA) Stock Price & Analysis
Tenaya Therapeutics, Inc. (TNYA) rose 0.25% to USD 0.78 as of July 26, 2026 at 11:55 UTC, according to Nexqual real-time market data.
TNYA last closed at USD 0.77; the session ranged USD 0.75–0.79 on volume of 1,792,597 shares. Market capitalization is $168.17M, with a 52-week range of USD 0.53–2.35 (NMS). Source: Nexqual, July 26, 2026 at 11:55 UTC.
Key Statistics (as of July 26, 2026 at 11:55 UTC)
| Price | USD 0.78 |
|---|---|
| Change | ▲ 0.25% (up) |
| Previous Close | USD 0.77 |
| Open | USD 0.77 |
| Day Range | USD 0.75 – 0.79 |
| 52-Week Range | USD 0.53 – 2.35 |
| Volume | 1,792,597 shares |
| Market Cap | $168.17M |
| Exchange | NMS |
Technical Analysis (TNYA)
Nexqual's technical model rates TNYA "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 26, 2026 at 11:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.23 (neutral) |
| vs SMA50 | Below (USD 0.79) |
| MACD | 0.01 (positive) |
Analyst Ratings (TNYA)
Wall Street analysts rate TNYA "Strong Buy" based on 6 analysts, with a mean price target of USD 4 (range USD 2–8), per Nexqual as of July 26, 2026 at 11:55 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 4 |
| High Target | USD 8 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (TNYA)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.06 |
| Revenue Estimate | $10.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.09 vs est -0.09 ▼ miss |
| 2025-12-31 | USD -0.12 vs est -0.12 ▲ beat |
| 2025-09-30 | USD -0.12 vs est -0.15 ▲ beat |
| 2025-06-30 | USD -0.14 vs est -0.19 ▲ beat |
Source: Nexqual, July 26, 2026 at 11:55 UTC.
Financials & Fundamentals (TNYA)
| Total Revenue | $225,000 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -8917.78% |
| Profit Margin | +0.00% |
| ROE | -73.59% |
| Debt / Equity | 9.53 |
| Current Ratio | 5.75 |
| Total Cash | $80.89M |
| Total Debt | $10.12M |
| Free Cash Flow | $-41.90M |
Source: Nexqual, July 26, 2026 at 11:55 UTC.
Financial Health Score (TNYA)
Nexqual rates Tenaya Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 11:55 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $81M cash vs $10M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$64M |
| Efficiency | Critical — ROE -74%, ROA -38.5% |
Ownership (TNYA)
| Insider Ownership | +0.47% |
|---|---|
| Institutional Ownership | +48.27% |
| Shares Outstanding | 217.00M |
| Float | 216.07M |
| Short % of Float | +14.93% |
Source: Nexqual, July 26, 2026 at 11:55 UTC.
Leadership (TNYA)
Tenaya Therapeutics, Inc. is led by Deepak Srivastava (age 58), Scientific Founder, Chairman of Scientific Advisory Board & Director, per Nexqual as of July 26, 2026 at 11:55 UTC.
| Scientific Founder, Chairman of Scientific Advisory Board & Director | Deepak Srivastava (age 58) |
|---|---|
| Chief Technology Officer | Kee-Hong Kim (age 59) |
| Vice President of Investor Relationship & Corporate Communications | Michelle Corral |
Major Backers & Investors (TNYA)
Notable institutional backers of Tenaya Therapeutics, Inc. include Millennium Management, Empery Asset Management, LP, Citadel, according to Nexqual as of July 26, 2026 at 11:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Millennium Management | 2.51% |
| Empery Asset Management, LP | 1.98% |
| Citadel | 1.94% |
| Renaissance Technologies | 1.71% |
| Marshall Wace LLP | 1.25% |
| Kalehua Capital Management LLC | 0.92% |
| Burkehill Global Management, LP | 0.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.71% |
| BlackRock | 2.25% |
| Geode Capital | 0.72% |
Source: Nexqual, July 26, 2026 at 11:55 UTC.
From Tenaya Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
- Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
- The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration.
- It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc. | USD 2.03 | ▲ 0.5% |
| TSHA | Taysha Gene Therapies, Inc. | USD 5.52 | ▼ 2.47% |
| IMRX | Immuneering Corporation | USD 4.32 | ▼ 3.36% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.43 | ▲ 16.99% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 22.78 | ▼ 4.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:55 UTC. This page is informational and not investment advice.